A Systematic Review and Meta-Analysis of Endocrine-R with Immune Checkpoint Inhibitors

Hormone and Metabolic Research 51, 145-156 DOI: 10.1055/a-0843-3366

Citation Report

#	Article	IF	CITATIONS
1	Cancer immunotherapy-associated hypophysitis. Future Oncology, 2019, 15, 3159-3169.	2.4	24
2	Immunotherapy of brain metastases: breaking a "dogma― Journal of Experimental and Clinical Cancer Research, 2019, 38, 419.	8.6	70
3	Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. , 2019, 7, 286.		92
4	Immune checkpoint inhibitorâ€associated pituitaryâ€adrenal dysfunction: A systematic review and metaâ€analysis. Cancer Medicine, 2019, 8, 7503-7515.	2.8	35
5	Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency. BMJ Case Reports, 2019, 12, e231236.	0.5	13
6	Acute and Long-term Adverse Events Associated With Checkpoint Blockade. Seminars in Oncology Nursing, 2019, 35, 150926.	1.5	7
7	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. International Journal of Molecular Sciences, 2019, 20, 2560.	4.1	72
9	Type 1 diabetes mellitus in a melanoma patient treated with adjuvant nivolumab therapy. Journal of Cutaneous Immunology and Allergy, 2019, 2, 176-177.	0.3	1
10	Immunotherapy-induced endocrinopathies: assessment, management and monitoring. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881989618.	3.2	29
11	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. Journal of Biomedical Science, 2019, 26, 96.	7.0	26
13	New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101370.	4.7	60
14	Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event. International Immunopharmacology, 2020, 89, 107050.	3.8	7
15	Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report. Journal of Medical Case Reports, 2020, 14, 171.	0.8	12
16	Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. Cancers, 2020, 12, 3446.	3.7	19
17	Immune Related Adverse Events. Cancer Journal (Sudbury, Mass), 2020, 26, 432-440.	2.0	4
19	Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma. Journal of Investigative Medicine High Impact Case Reports, 2020, 8, 232470962095133.	0.6	7
20	History of Radiation to the Neck Increases the Risk of Denovo Thyroid Dysfunction after Receiving Immune Checkpoint Inhibitors. Endocrines, 2020, 1, 82-89.	1.0	0
21	Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up. Journal of Clinical Medicine, 2020, 9, 3280.	2.4	27

λτιών Ρέρω

#	Article	IF	CITATIONS
22	Development of Overt Thyroid Dysfunction and Antithyroid Antibodies with Anti-PD-1 Use in Various Cancers Is Associated with Favorable Survival. Clinical Thyroidology, 2020, 32, 221-224.	0.1	1
23	Side effect management during immune checkpoint blockade using CTLAâ€4 and PDâ€1 antibodies for metastatic melanoma – an update. JDDG - Journal of the German Society of Dermatology, 2020, 18, 582-609.	0.8	24
24	In Reply — Immune Checkpoint Inhibitor–Induced Type 1 Diabetes: An Underestimated Risk. Mayo Clinic Proceedings, 2020, 95, 615.	3.0	0
25	Immunoassay Interference on Thyroid Function Tests During Treatment with Nivolumab. Thyroid, 2020, 30, 1091-1094.	4.5	9
26	Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. Internal and Emergency Medicine, 2020, 15, 587-598.	2.0	16
27	Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101411.	4.7	16
28	Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. Immune Network, 2020, 20, e9.	3.6	143
29	Thyroiditis While Receiving Programmed Death Ligand 1 (PD-L1) Inhibitor Therapy for Nonthyroid Cancers Is Associated with Improved Overall Survival. Clinical Thyroidology, 2020, 32, 65-68.	0.1	2
30	Immune Checkpoint Inhibitor–Induced Type 1 Diabetes: An Underestimated Risk. Mayo Clinic Proceedings, 2020, 95, 614-615.	3.0	3
31	Graves' disease. Nature Reviews Disease Primers, 2020, 6, 52.	30.5	199
32	Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review. Journal of Clinical Medicine, 2020, 9, 2033.	2.4	13
33	Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 91.	2.8	112
34	A review of cancer immunotherapy toxicity. Ca-A Cancer Journal for Clinicians, 2020, 70, 86-104.	329.8	753
35	Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis. Medicine (United States), 2020, 99, e18701.	1.0	1
36	Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy. International Immunopharmacology, 2020, 83, 106427.	3.8	23
37	Autoimmune complications of immunotherapy: pathophysiology and management. BMJ, The, 2020, 369, m736.	6.0	79
38	Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 258.	2.8	35
39	Immune checkpoints inhibitors and hyperglycemia: A Meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2020, 162, 108115.	2.8	8

#	Article	IF	CITATIONS
40	Diabetes mellitus induced by immune checkpoint inhibitors. Diabetes/Metabolism Research and Reviews, 2021, 37, e3366.	4.0	12
41	Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis. Canadian Journal of Diabetes, 2021, 45, 186-197.e2.	0.8	22
42	In Reply. Oncologist, 2021, 26, e192-e193.	3.7	0
43	Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review. Cancer Immunology, Immunotherapy, 2021, 70, 1527-1540.	4.2	21
44	Case series review of neuroradiologic changes associated with immune checkpoint inhibitor therapy. Neuro-Oncology Practice, 2021, 8, 247-258.	1.6	3
45	Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors. Annual Review of Medicine, 2021, 72, 313-330.	12.2	24
46	Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies. European Endocrinology, 2021, 1, 21.	1.5	0
47	Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?. European Journal of Endocrinology, 2021, 184, K1-K5.	3.7	37
48	The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma. Biomedicines, 2021, 9, 98.	3.2	8
49	Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies. European Endocrinology, 2021, 17, 21.	1.5	7
50	A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 753-757.	2.4	6
51	Endocrine complications of immunotherapies: a review. Clinical Medicine, 2021, 21, e212-e222.	1.9	29
52	Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell, 2021, 184, 1575-1588.	28.9	111
53	Endokrynologiczne powikÅ,ania nowych terapii przeciwnowotworowych. Postepy Higieny I Medycyny Doswiadczalnej, 2021, 75, 191-198.	0.1	0
54	A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. Journal of Medical Toxicology, 2021, 17, 411-424.	1.5	54
55	Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces. Expert Opinion on Biological Therapy, 2021, 21, 1097-1120.	3.1	5
56	Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). Cancers, 2021, 13, 1944.	3.7	21
57	Endocrine toxicities of immune checkpoint inhibitors. Nature Reviews Endocrinology, 2021, 17, 389-399.	9.6	162

#	Article	IF	CITATIONS
58	Biotin-induced thyroid stimulating hormone aberrations in the setting of immunotherapy. Journal of Oncology Pharmacy Practice, 2021, 27, 2057-2060.	0.9	1
59	Th17 Cells Contribute to the Pathology of Autoimmune Hypophysitis. Journal of Immunology, 2021, 206, 2536-2543.	0.8	12
60	A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab. American Journal of Case Reports, 2021, 22, e931702.	0.8	10
61	The influence of monoclonal antibodies for cancer treatment on the endocrine system. Postepy Higieny I Medycyny Doswiadczalnej, 2021, 75, 317-327.	0.1	0
62	Management of adverse events in cancer treatment with immune checkpoint inhibitors. Journal of the Korean Medical Association, 2021, 64, 358-365.	0.3	0
63	Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors. Journal of the Endocrine Society, 2021, 5, bvab100.	0.2	9
64	Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management. Frontiers in Endocrinology, 2021, 12, 649863.	3.5	24
65	Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report. Frontiers in Immunology, 2021, 12, 606056.	4.8	5
66	Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies. Melanoma Research, 2021, 31, 208-217.	1.2	8
67	The Diagnosis and Management of Endocrine Side Effects of Immune Checkpoint Inhibitors. Deutsches Ärzteblatt International, 2021, 118, .	0.9	7
68	Programmed Cell Death-Ligand 1 (PD-L1) gene Single Nucleotide Polymorphism in Graves' Disease and Hashimoto's Thyroiditis in Korean Patients. Endocrinology and Metabolism, 2021, 36, 599-606.	3.0	2
69	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
70	Endocrine adverse effects of immune checkpoint inhibitors. Internal Medicine Journal, 2021, 51, 1016-1020.	0.8	2
71	Abdominal pain as an initial symptom of isolated ACTH deficiency induced by nivolumab in a patient with malignant mesothelioma. BMJ Case Reports, 2021, 14, e243093.	0.5	1
72	Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. Cancers, 2021, 13, 4036.	3.7	3
73	Anti-PD-1 treatment-induced immediate central diabetes insipidus: aÂcase report. Immunotherapy, 2021, 13, 1255-1260.	2.0	13
74	Recent insights into the pathogenesis of autoimmune hypophysitis. Expert Review of Clinical Immunology, 2021, 17, 1175-1185.	3.0	7
75	Differences between immunotherapy-induced and primary hypophysitis—a multicenter retrospective study. Pituitary, 2021, , 1.	2.9	15

#	Article	IF	CITATIONS
76	Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes. Endocrine Practice, 2021, 27, 886-893.	2.1	9
77	Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report. Urology Case Reports, 2021, 38, 101661.	0.3	3
78	Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review. ESMO Open, 2021, 6, 100276.	4.5	28
79	Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. Lung Cancer, 2021, 161, 34-41.	2.0	7
80	Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors. Asia-Pacific Journal of Oncology Nursing, 2021, 8, 596-603.	1.6	6
81	Autoimmune diabetes insipidus. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 181, 193-204.	1.8	8
82	Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors. Current Cancer Research, 2021, , 139-173.	0.2	0
83	Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study. Cancer Immunology, Immunotherapy, 2021, 70, 2023-2033.	4.2	24
84	Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. Journal of Endocrinological Investigation, 2021, 44, 1719-1726.	3.3	21
85	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. Journal of Clinical Investigation, 2020, 130, 51-61.	8.2	66
86	Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocrine Connections, 2020, 9, R207-R228.	1.9	66
87	Anticancer Medications and Sodium Dysmetabolism. European Endocrinology, 2020, 16, 122.	1.5	9
88	An Update on Immune Checkpoint Inhibitor-related Hypophysitis. US Endocrinology, 2020, 16, 117.	0.3	3
89	Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians. Immunotherapy, 2020, 12, 481-510.	2.0	7
90	Real-World Incidence of Immune-Related Adverse Events Associated with Nivolumab Plus Ipilimumab in Patients with Advanced Renal Cell Carcinoma: A Retrospective Observational Study. Journal of Clinical Medicine, 2021, 10, 4767.	2.4	3
91	An Evanishing Thyroid During Immune Checkpoint Inhibitor Therapy. Clinical Nuclear Medicine, 2021, Publish Ahead of Print, .	1.3	2
92	The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries. Cancers, 2021, 13, 5277.	3.7	12
95	Side effects and management in immunotherapy based on immune checkpoint inhibitors. World Chinese Journal of Digestology, 2020, 28, 755-764.	0.1	1

		Report	
#	Article	IF	Citations
96	Severe oral ulcerative and lichenoid lesions associated with adrenal insufficiency in a patient treated with nivolumab: Report of a case and review of literature. Special Care in Dentistry, 2021, , .	0.8	2
97	latrogenic Hypothalamic Disorders. Contemporary Endocrinology, 2021, , 497-518.	0.1	0
98	Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies. Frontiers in Pharmacology, 2021, 12, 747416.	3.5	0
99	Immune-related Pulmonary Toxicity From Cancer Immunotherapy: A Systematic Approach. Clinical Pulmonary Medicine, 2020, 27, 183-192.	0.3	0
100	Endocrine Late Effects in Young Cancer Patients: Adrenal Gland. , 2021, , 101-106.		0
101	Familial associations for Addison's disease and between Addison's disease and other autoimmune diseases. Endocrine Connections, 2020, 9, 1114-1120.	1.9	0
102	Pembrolizumab-Induced Type 1 Diabetes in a 95-Year-Old Veteran With Metastatic Melanoma. , 2021, 38, 520-523.		1
103	The changing clinical spectrum of endocrine adverse events in cancer immunotherapy. Trends in Endocrinology and Metabolism, 2022, 33, 87-104.	7.1	11
104	Familial associations for Addison's disease and between Addison's disease and other autoimmune diseases. Endocrine Connections, 2020, 9, 1114-1120.	1.9	2
105	Sex Differences in Immunity. Annual Review of Immunology, 2022, 40, 75-94.	21.8	47
106	Endocrine Toxicities of Antineoplastic Therapy: The Adrenal Topic. Cancers, 2022, 14, 593.	3.7	6
107	Sintilimab-induced autoimmune diabetes: A case report and review of the literature. World Journal of Clinical Cases, 2022, 10, 1263-1277.	0.8	3
108	Risk assessment, diagnosis, and treatment of cancer treatment-related adrenal insufficiency. Expert Review of Endocrinology and Metabolism, 2022, 17, 21-33.	2.4	3
109	Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunology, Immunotherapy, 2022, 71, 1795-1812.	4.2	31
111	Immune-checkpoint inhibitors: long-term implications of toxicity. Nature Reviews Clinical Oncology, 2022, 19, 254-267.	27.6	360
113	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. Experientia Supplementum (2012), 2022, 113, 295-350.	0.9	3
114	Immune Checkpoint Inhibitors as a Threat to the Hypothalamus–Pituitary Axis: A Completed Puzzle. Cancers, 2022, 14, 1057.	3.7	4
115	Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2022, 36, 101635.	4.7	10

#	Article	IF	CITATIONS
116	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Frontiers in Immunology, 2022, 13, 804597.	4.8	27
117	When therapeutic drugs lead to diabetes. Diabetologia, 2022, 65, 751-762.	6.3	12
118	lt's Not Always SIAD: Immunotherapy-Triggered Endocrinopathies Enter the Field of Cancer-Related Hyponatremia. Journal of the Endocrine Society, 2022, 6, bvac036.	0.2	4
119	Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?. Frontiers in Oncology, 2022, 12, 798517.	2.8	9
120	Immunotherapy-Associated Hypothyroidism: Comparison of the Pre-Existing With De-Novo Hypothyroidism. Frontiers in Endocrinology, 2022, 13, 798253.	3.5	3
121	Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews. Drugs, 2022, , .	10.9	3
122	Immune-Related Adverse Events (irAEs) in Cancer, with Inputs from a Nursing Expert: A Review. Indian Journal of Medical and Paediatric Oncology, 0, 43, .	0.2	0
123	A decrease in peripheral thyroid hormone conversion efficiency in patients treated with immune checkpoint inhibitors and Lâ€73 as a possible alternative therapeutic escape option. European Journal of Clinical Investigation, 2022, , e13790.	3.4	1
126	The side effects of immune checkpoint inhibitor therapy on the endocrine system. Indian Journal of Medical Research, 2021, 154, 559.	1.0	7
128	American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach. Endocrine Practice, 2022, 28, 719-731.	2.1	12
129	Real-world data on the incidence of immune-related adverse events associated with anti-PD-1/PD-L1 treatment in Russia. Voprosy Onkologii, 2022, 68, 188-199.	0.2	3
130	Thyroid Dysfunction from Treatments for Solid Organ Cancers. Endocrinology and Metabolism Clinics of North America, 2022, 51, 265-286.	3.2	3
132	Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment. Cancers, 2022, 14, 2687.	3.7	10
133	Top Ten Tips Palliative Care Clinicians Should Know About Managing Immune-Mediated Endocrine Toxicities in Cancer. Journal of Palliative Medicine, 0, , .	1.1	0
134	Anti-programmed Cell Death Protein-1 Therapy in Intrahepatic Cholangiocarcinoma Induced Type 1 Diabetes: A Case Report and Literature Review. Frontiers in Public Health, 0, 10, .	2.7	2
135	Neurologic Complications of Immune Checkpoint Inhibitors. Touch Reviews in Neurology, 2022, 18, 58.	0.2	0
136	Research progress on immunotherapy in triple‑negative breast cancer (Review). International Journal of Oncology, 2022, 61, .	3.3	9
137	The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists.	3.1	0

	CITATIO	on Report	
#	Article	IF	CITATIONS
138	Monitoring Endocrine Complications of Immunotherapy: A Screening Tool. Cureus, 2022, , .	0.5	3
139	Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy. Frontiers in Oncology, 0, 12, .	2.8	9
140	Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. Journal of Immunology, 2022, 209, 696-709.	0.8	14
141	Imaging features of toxicities associated with immune checkpoint inhibitors. European Journal of Radiology Open, 2022, 9, 100434.	1.6	6
142	Fertility preservation for patients with melanoma. Melanoma Research, O, Publish Ahead of Print, .	1.2	2
143	Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduction and Targeted Therapy, 2022, 7, .	17.1	142
144	A systematic review and meta-analysis of endocrine-related adverse events associated with interferon. Frontiers in Endocrinology, 0, 13, .	3.5	0
145	Research progress of neoantigens in gynecologic cancers. International Immunopharmacology, 2022, 112, 109236.	3.8	5
146	Previous therapy with immune checkpoint inhibitor as a cause of hypothyroidism, myositis, and renal insufficiency in a candidate for allogeneic hematopoietic transplantation. Transplant Immunology, 2022, 75, 101705.	1.2	2
147	Anti-neoplastic Immunomodulatory Treatments and the Pituitary. , 2022, , 309-320.		0
148	Endocrine. , 2022, , 59-79.		0
149	Severe Immune-Related Adverse Events: A Case Series of Patients Needing Hospital Admission in a Spanish Oncology Referral Center and Review of the Literature. Diagnostics, 2022, 12, 2116.	2.6	1
150	Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. European Journal of Endocrinology, 2022, 187, G1-G21.	3.7	35
151	Thyroid-related adverse events induced by immune checkpoint inhibitors. Frontiers in Endocrinology, 0, 13, .	3.5	9
152	Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer. Frontiers in Pharmacology, 0, 13, .	3.5	8
153	Thyroid Dysfunction in Non–Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Metaâ€Analysis. Journal of Clinical Pharmacology, 0, , .	2.0	0
154	Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2022, 33, 1217-1238.	1.2	204
155	Hypophysitis induced by anti-programmed cell death protein 1 immunotherapy in non-small cell lung cancer: Three case reports. World Journal of Clinical Cases, 0, 10, 11049-11058.	0.8	3

#	Article	IF	CITATIONS
157	Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non–Small Cell Lung Cancer. Radiographics, 2022, 42, 1956-1974.	3.3	4
158	Immunotherapy and Endocrine Oncology. , 2022, , 1-36.		Ο
159	The Flip of the Coin of Personalized Cancer Immunotherapy: A Focused Review on Rare Immune Checkpoint Related Adverse Effects. , 0, , .		0
160	Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms. BMC Endocrine Disorders, 2022, 22, .	2.2	3
162	Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society. Endocrinology and Metabolism, 2022, 37, 839-850.	3.0	3
163	Approach to the Patient With Immune Checkpoint Inhibitor–Associated Endocrine Dysfunction. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 1514-1525.	3.6	8
164	Isolated adrenocorticotropic hormone deficiency and sialadenitis associated with nivolumab: a case report. Journal of Medical Case Reports, 2022, 16, .	0.8	3
165	Drugs and Pituitary Function. , 2022, , 413-427.		0
166	Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment. Cancers, 2023, 15, 375.	3.7	10
167	Immune checkpoint blockade PD-1 therapy for primary liver cancer: incidence and influencing factors of thyroid dysfunction. Infectious Agents and Cancer, 2022, 17, .	2.6	1
168	Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis. International Journal of Molecular Sciences, 2023, 24, 599.	4.1	5
169	Incidence of endocrine-related immune-related adverse events in Japanese subjects with various types of cancer. Frontiers in Endocrinology, 0, 14, .	3.5	1
170	Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features. Journal of Cancer Research and Clinical Oncology, 2023, 149, 7925-7932.	2.5	2
171	Surgery in the Era of Immunotherapy for Advanced Head and Neck Non-melanoma Skin Cancer. Current Oncology Reports, 2023, 25, 735-742.	4.0	3
172	Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes and Endocrinology,the, 2023, 11, 282-298.	11.4	30
173	Nebenwirkungen und deren Management. , 2022, , 121-146.		0
174	Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors. Immuno-Oncology Technology, 2023, 17, 100374.	0.3	4
175	Thrombospondin-1, CD47, and SIRPα display cell-specific molecular signatures in human islets and pancreata. American Journal of Physiology - Endocrinology and Metabolism, 2023, 324, E347-E357.	3.5	3

#	Article	IF	CITATIONS
176	Development of three endocrinopathies under nivolumab therapy. Alʹmanah KliniÄeskoj Mediciny, 2023, 50, 490-496.	0.3	0
177	Imaging assessment of toxicity related to immune checkpoint inhibitors. Frontiers in Immunology, 0, 14, .	4.8	6
178	Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy. , 2023, , 1-32.		0
180	A real-world retrospective study of incidence and associated factors of endocrine adverse events related to PD-1/PD-L1 inhibitors. Annals of Translational Medicine, 2023, 11, 164-164.	1.7	0
181	Endocrine and Neurological Toxicities of Immunotherapies. Praxis, 2023, 112, 178-183.	0.4	1
182	Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer. Journal of Personalized Medicine, 2023, 13, 526.	2.5	5
183	Immune checkpoint inhibitor-related thyroid dysfunction. Annales D'Endocrinologie, 2023, 84, 346-350.	1.4	2
184	Toxicity When Combining Immunotherapy and Radiotherapy. , 2023, , 1-32.		0
185	Pituitary hypoadrenocorticism and hypothyroidism after immunochemotherapy followed by salvage surgery for lung cancer: a case report. , 2023, 2, .		0
186	The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events. Cancers, 2023, 15, 2016.	3.7	3
187	Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients. Cancer Immunology, Immunotherapy, 0, , .	4.2	1
188	Correction of endocrine complications of oncoimmunotherapy. Obesity and Metabolism, 2023, 19, 418-430.	1.2	0
189	A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2023, 24, 7630.	4.1	1
190	Inflammatory and Infectious Disorders in Endocrine Pathology. Endocrine Pathology, 2023, 34, 406-436.	9.0	5
191	Toxicities associated with immune checkpoint inhibitors: a systematic study. International Journal of Surgery, 2023, 109, 1753-1768.	2.7	4
192	Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review. Current Oncology, 2023, 30, 4700-4723.	2.2	4
193	Inhibition of tumor immune escape by blocking PD-1/PD-L1 engagement with dual-targeting molecularly imprinted polymer layer. Cancer Nanotechnology, 2023, 14, .	3.7	1
194	Clonally expanded, thyrotoxic effector CD8 ⁺ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis. Science Translational Medicine, 2023, 15, .	12.4	7

#	Article	IF	CITATIONS
195	Immune-related adverse events of immune checkpoint inhibitors: a review. Frontiers in Immunology, 0, 14, .	4.8	18
196	Immune mechanisms of toxicity from checkpoint inhibitors. Trends in Cancer, 2023, 9, 543-553.	7.4	17
197	Progress and Challenges of Immune Checkpoint Inhibitor-Induced Hypophysitis. Journal of Clinical Medicine, 2023, 12, 3468.	2.4	0
198	Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 2916-2923.	3.6	1
199	The Impact of Systemic Oncological Treatments on the Fertility of Adolescents and Young Adults—A Systematic Review. Life, 2023, 13, 1209.	2.4	5
200	Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus. International Immunopharmacology, 2023, 122, 110414.	3.8	2
201	Isolated adrenocorticotropic hormone deficiency following immune checkpoint inhibitors treatment often occurs in polyglandular endocrinopathies. BMC Endocrine Disorders, 2023, 23, .	2.2	1
202	Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events. , 2023, 40, .		4
203	Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions. Immunological Reviews, 0, , .	6.0	1
204	ϴΫϴžϴʹϴϯϴͽϴϿ·ϴϯϿ΅ϴ¢ϴ•ϴϴϴΫϴϯϴ‡ϴϯϴϴʹʹϴϯϴʹϴϯϴͼϴžϴϴϿͼϴ΅ϴ΅ϴͼϴϗϴϴϿʹϴ¥ͺϴϗϴžϴϴͼϴϽͽϧϴϧϴ	ĵ~Đ¥j₫¢Đž	ЧОК ÐÐ <mark>≁</mark> ∂
204 205	ПОÐʻІЧÐЕДІÐ ⁻ ТЕÐÐПІЇ ІÐГІÐʻІТОÐĐĐ@Đ ⁻ Ð ⁻ ÐœĐ£ĐĐĐ ⁻ Đ¥ ÐšĐžĐĐ¢ĐĐžĐ›Ð¬Đ€ Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, .) [~] Х)ТО 17.1	ЧОК ÐÐ 5
204 205 207	DŸĐžĐʻІЧĐЕДІĐ ⁻ Đ¢Đ•ĐĐĐŸĐ†Đ‡ ІĐГІĐʻĐ†Đ¢ĐžĐĐĐœĐ ⁻ Đ ⁻ ĐœĐ£ĐĐĐ ⁻ Đ¥ ЧОĐĐ¢ĐОЕЬЀ Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, . Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening. Biosensors and Bioelectronics, 2023, 240, 115644.)°Ð¥ðТО 17.1 10.1	ЧОК ÐÐ 5 6
204 205 207 208	DŸĐžĐ'ІĐ\$ĐĐ•Đ"Đ†Đ Đ¢Đ•ĐĐĐŸĐ†Đ‡ ІĐГІĐ'Đ†Đ¢ĐžĐĐĐĐœĐ Đ ĐœĐ£ĐĐĐĐ Đ¥ КОĐĐ¢ĐĐžĐ>Đ-Đ€ Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, . Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening. Biosensors and Bioelectronics, 2023, 240, 115644. Immune Checkpoint Inhibitor-Induced Endocrine Adverse Events in Cancer Patients at a Tertiary Care Center in Saudi Arabia. Cureus, 2023,)°Ð¥ðТО 17.1 10.1 0.5	ÐŞÐŽÐŠ ÐÐ 5 6 0
204 205 207 208 209	 ĐŸĐžĐ'ІĐ\$ĐĐ-Đ"Đ†Đ Đ¢Đ-ĐĐĐŸĐ†Đ‡ ІĐĐ"ІĐ'Đ†Đ¢Đ‡ĐĐĐœĐ Đ ĐœĐ£ĐĐĐĐ Đ¥ Đ\$ĐžĐĐ¢ĐĐžĐ)Đ ĐĐ Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, . Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening. Biosensors and Bioelectronics, 2023, 240, 115644. Immune Checkpoint Inhibitor-Induced Endocrine Adverse Events in Cancer Patients at a Tertiary Care Center in Saudi Arabia. Cureus, 2023, ,. Endocrine immune-related adverse effects of immune-checkpoint inhibitors. Expert Review of Endocrinology and Metabolism, 2023, 18, 441-451.) [•] Ð¥∂ТО 17.1 10.1 0.5 2.4	ÐSОК ÐÐ Ð
204 205 207 208 209 210	 DŸĐžĐ'ІĐ\$ĐĐ-Đ"Đ†Đ Đ¢Đ-ĐĐĐŸĐ†Đ‡ ІĐГІĐ'Đ†Đ¢ĐžĐĐĐœĐ Đ ĐœĐ£ĐĐĐ Đ¥ КОĐĐ¢ĐĐžĐ>Đ-Đ€ Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, . Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening. Biosensors and Bioelectronics, 2023, 240, 115644. Immune Checkpoint Inhibitor-Induced Endocrine Adverse Events in Cancer Patients at a Tertiary Care Center in Saudi Arabia. Cureus, 2023, , . Endocrine immune-related adverse effects of immune-checkpoint inhibitors. Expert Review of Endocrinology and Metabolism, 2023, 18, 441-451. Adverse event costs associated with first-line therapy for advanced non–small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors. Journal of Managed Care & amp; Specialty Pharmacy, 2023, 29, 1054-1064. 	D`Đ₩Đ¢Đž 17.1 10.1 0.5 2.4 0.9	ÐSÐZÐS ÐÐ -Ð 5 6 0 0
204 205 207 208 209 210	DŸĐZĐ'ІĐ\$ĐĐ-Đ"Đ†Đ Đ¢Đ-ĐĐĐŸĐ†Đ‡ ІĐĐ"ІĐ'Đ†Đ¢Đ‡ĐĐĐœĐ Đ ĐœĐ£ĐĐĐ Đ¥ Đ\$ĐZĐĐ¢ĐĐZĐ-Đ-Đệ Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, . Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening. Biosensors and Bioelectronics, 2023, 240, 115644. Immune Checkpoint Inhibitor-Induced Endocrine Adverse Events in Cancer Patients at a Tertiary Care Center in Saudi Arabia. Cureus, 2023, , . Endocrine immune-related adverse effects of immune-checkpoint inhibitors. Expert Review of Endocrinology and Metabolism, 2023, 18, 441-451. Adverse event costs associated with first-line therapy for advanced non–small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors. Journal of Managed Care & Specialty Pharmacy, 2023, 29, 1054-1064.	D°Đ₩Đ¢Đž 17.1 10.1 0.5 2.4 0.9 2.8	ÐSÐZЊ ÐÐ - Ð 5 6 0 0 0
204 205 207 208 209 210 211	 BŸĐźĐ'ІĐ\$ĐĐ-Đ"ІĐ" Đ¢Đ-ĐĐĐŸD†Đ‡ ІĐĐ"ІĐ'Đ†Đ¢Đ‡ĐĐĐœĐ" Đ"ĐœĐ£ĐĐĐ Đ¥ КПĐĐ¢ĐĐŽĐ,Đ-Đ€ Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, . Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening. Biosensors and Bioelectronics, 2023, 240, 115644. Immune Checkpoint Inhibitor-Induced Endocrine Adverse Events in Cancer Patients at a Tertiary Care Center in Saudi Arabia. Cureus, 2023, , . Endocrine immune-related adverse effects of immune-checkpoint inhibitors. Expert Review of Endocrinology and Metabolism, 2023, 18, 441-451. Adverse event costs associated with first-line therapy for advanced nonâ€"small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors. Journal of Managed Care & amp; Specialty Pharmacy, 2023, 29, 1054-1064. Severe thyrotoxicosis induced by tislelizumab: a case report and literature review. Frontiers in Oncology, 0, 13, . Clinically Approved Monoclonal Antibodiesâ€"based Immunotherapy: Association With Glycemic Control and Impact Role of Clinical Pharmacist for Cancer Patient Care. Clinical Therapeutics, 2024, 46, e29-e44. 	D°Ð¥ðТО 17.1 10.1 0.5 2.4 0.9 2.8 2.5	ÐSÐZЊ ÐÐ -) 5 6 0 0 0 1 1

		CITATION REPOR	т
#	Article	IF	Citation
215	Durvalumab-Associated Hypopituitarism. American Journal of Therapeutics, 2023, 30, e	583-e586. 0.9	0
216	Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Chec Inhibitors: A Meta-Analysis and Comprehensive Review. Endocrinology and Metabolism,	kpoint 3.0 0, , .	0
217	Providing Clarity Regarding the Mechanism for Immune Checkpoint Inhibitor–Associa Clinical Thyroidology, 2023, 35, 443-446.	ted Thyroiditis. 0.1	. 0
219	Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinic radiological aspects. Seminars in Oncology, 2023, , .	al, and 2.2	2
220	Diabetes management in cancer patients. An Italian Association of Medical Oncology, It Association of Medical Diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position Open, 2023, 8, 102062.	alian paper. ESMO 4.5	0
221	Incidence and Timing of Immune-Related Adverse Events in Immune-Checkpoint Inhibito Patients: A Retrospective Observational Study. Journal of Clinical Medicine, 2023, 12, 75	r-Treated 2.4 564. 2.4	1
222	Common endocrine system adverse events associated with immune checkpoint inhibito	ors. , 2023, , .	0
223	Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoi Therapy. Cancers, 2023, 15, 5786.	nt Inhibitor 3.7	3
224	Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoin combination therapy with nivolumab and ipilimumab: A case report. Medicine (United S e36664.	1t inhibitor tates), 2023, 102, 1.0	1
225	Immunotherapy-Induced Hypophysitis Following ICI Treatment With Tislelizumab in an I With Bladder Cancer and Prostate Cancer: A Case Report. Cureus, 2023, , .	Elderly Patient 0.5	0
226	Immune Checkpoint Inhibition. , 2024, , 1-91.		0
227	Drug-induced hyperglycemia and diabetes. Therapie, 2023, , .	1.0	1
228	Impact of Systemic Therapy on Fertility in Women with Early-Stage Breast Cancer. Curre Cancer Reports, 2024, 16, 61-68.	ent Breast 1.0	0
229	The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors or Function. Thyroid, 2024, 34, 158-166.	1 Thyroid 4.5	0
230	Adrenal crisis mainly manifested as recurrent syncope secondary to tislelizumab: a case literature review. Frontiers in Immunology, 0, 14, .	report and 4.8	1
231	Cancer immunotherapy-associated endocrine complications and treatment strategies. ,	2024,,199-221.	О
232	Research Advances of Immune Checkpoint Inhibitors Related Endocrine Adverse Events. Clinical Medicine, 2024, 14, 2706-2716.	Advances in 0.0) 0
233	PD-1/PD-L1 inhibitors associated hypophysitis: An analysis from the FAERS database and Drug Discoveries and Therapeutics, 2024, 18, 34-43.	case reports. 1.5	0

CITATION	REPORT
CHAILON	KLI OKI

#	Article	IF	CITATIONS
234	Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. , 2024, 12, e008735.		0